Aurora (ACB) Q4 2026 earnings review
Record Year Eclipsed by Margin Collapse and Bleak FY27 Outlook
Aurora successfully completed its transformation into a pure-play global medical cannabis operator by divesting Bevo Agtech and functionally winding down its consumer business. While Q4 continuing operations revenue grew 10% YoY, the quality of earnings deteriorated sharply. Medical gross margins slipped to 66% from 71% due to strategic price reductions, driving Adjusted EBITDA down 34% YoY. The real shock came in the FY27 guidance: sweeping reimbursement cuts in Canada will offset European growth, forcing total revenue and EBITDA to reverse course and decline next year. Management's narrative of continuous profitable expansion has hit a hard regulatory wall.
🐂 Bull Case
Medical cannabis now drives 91% of consolidated net revenue. Growth in Germany and Poland helped medical revenue climb 14% YoY, validating the strategic pivot away from the hyper-competitive consumer market.
The $26.5M acquisition of Safari Flower Company adds 59,000 square feet of EU-GMP indoor capacity. This internalizes supply for booming European markets, reducing reliance on lower-margin third-party sourcing.
🐻 Bear Case
Changes to government reimbursed pricing in Canada (taking effect April 1, 2026) are devastating the FY27 outlook. Management expects total revenue to regress to FY25 levels alongside a lower annual Adjusted EBITDA.
Medical adjusted gross margins decelerated from 71% a year ago to 66% in Q4 due to price reductions. FY27 guidance of 'mid to high fifties' consolidated margin breaks the company's long-standing 60%+ target.
⚖️ Verdict: 🔴
Bearish. The strategic clean-up (Bevo exit, Safari acquisition) is logical, but the Canadian regulatory changes have broken the momentum. A reversing growth trajectory for FY27 overshadows the operational milestones.
Key Themes
Canadian Reimbursement Cuts Destroy Forward Growth
The regulatory risk flagged in Q2 regarding Canadian veteran medical reimbursements has materialized. The government reduced reimbursed pricing effective April 1, 2026. This single policy change is forcing Aurora to forecast a YoY decline in Total Net Revenue for FY27 (reverting to FY25 levels) and lower annual Adjusted EBITDA. International growth in Germany and Poland is explicitly not enough to offset this domestic revenue crater.
Safari Flower Acquisition Boosts EU-GMP Moat
Aurora acquired Safari Flower Company in April 2026 for $26.5M (cash and stock). This adds a critical 59,000 square foot EU-GMP certified indoor facility. This is a direct driver to feed accelerating demand in Germany and Poland with high-quality, internally cultivated flower, replacing margin-dilutive third-party wholesale purchasing.
Pure-Play Transition Complete
Management aggressively trimmed non-core segments. Consumer cannabis revenue plummeted 55% to $3.6M as the company winds down operations. Furthermore, the 50.1% divestiture of Bevo Agtech removes agricultural distraction and debt covenant headaches, allowing 100% of capital to flow into global medical cannabis.
SG&A Creep and Credit Losses
Adjusted SG&A decelerated the bottom line, climbing 14% YoY to $40.3M. Management cited higher headcount and European contract labor, but more alarmingly, recorded a $1.9M credit loss due to the insolvency of two customers. Operating leverage is moving in the wrong direction as expenses rise while margins fall.
Other KPIs
Decelerating violently from $5.2M in the prior year period and $18.5M in Q3. The $4.9M YoY drop was driven almost entirely by a $5.3M decrease in gross profit before fair value adjustments. While technically still positive, the margin for error has vanished ahead of a challenging FY27.
Reversing deeply from a $12.1M loss a year ago and positive $6.3M in Q3. The YoY expansion of the loss was primarily driven by negative swings in other income/expense ($11.9M income flipped to $1.7M expense) alongside rising SG&A.
Stable. The balance sheet remains a fortress with no cannabis-related debt. This liquidity buffer is critical to surviving the impending FY27 margin compression and funding the recent $15M cash component of the Safari acquisition.
Guidance
Reversing. After posting $320.6M in FY26, guiding back to FY25 levels (~$288M) implies an approximate 10% YoY contraction. Growth in Europe is failing to cover the hole left by Canadian medical pricing cuts.
Decelerating. Aurora has consistently touted a 60%+ margin target. Guiding down to the 50s acknowledges that higher-margin European growth cannot fully shield the portfolio from the Canadian reimbursement reset.
Reversing. Expected to vary quarter over quarter but decline annually. This breaks the multi-year narrative of consecutive EBITDA expansion, pointing to severe negative operating leverage as the top line shrinks.
Key Questions
Margin Floor Confidence
With Canadian medical margins resetting lower, what structural cost reductions are being enacted to ensure consolidated margins don't slip below the 'mid-fifties' guidance?
Safari Integration Timeline
How quickly will the 59,000 square feet of EU-GMP capacity from Safari Flower be online and actively displacing third-party wholesale costs in Europe?
European Pricing Power
You noted 'strategic price reductions' dragging down medical margins this quarter. Is this purely a Canadian phenomenon, or are you also seeing price compression in Germany as supply catches up to post-descheduling demand?